EPO revokes AstraZeneca’s pulmonary disease patent
One of AstraZeneca’s European patents covering Symbicort, a drug that treats pulmonary disease, has been revoked by the EPO following an appeal by generic manufacturers Norton Healthcare and Generics UK
The patent (EPB1014993) is one of two patents covering the Symbicort combination (formoterol and budesonide) used to treat chronic obstructive pulmonary disease.
The expiry date for the patent is 2018. The other patent covering the drug (EPB1210943) faces a separate...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.